- Current report filing (8-K)
10 May 2012 - 7:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
May 9, 2012
|
Biolase Technology, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
000-19627
|
87-0442441
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
4 Cromwell, Irvine, California
|
|
92618
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
949-361-1200
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2012, Biolase Technology, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2012. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
99.1 Press Release of Biolase Technology, Inc., dated May 9, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Biolase Technology, Inc.
|
|
|
|
|
|
May 9, 2012
|
|
By:
|
|
Federico Pignatelli
|
|
|
|
|
|
|
|
|
|
Name: Federico Pignatelli
|
|
|
|
|
Title: Chairman and Chief Executive Officer
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated May 9, 2012, of Biolase Technology, Inc.
|
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From May 2024 to Jun 2024
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Biolase Technology, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles